Drug Giants Cornered: Medicaid Flips The Script

Medicine cabinet with prescription bottles and toiletries — Photo: Kimberly Boyles / Shutterstock

When every state Medicaid program moves under a single pricing discipline tied to the lowest rates other wealthy countries pay, the center of gravity in U.S. drug purchasing shifts from list prices and opaque rebates to a firmer, reference-based ceiling—changing how states budget, how manufacturers negotiate, and how net prices are determined.

At a Glance

All 50 states, plus D.C. and Puerto Rico, are participating in an initiative to give Medicaid “most-favored-nation” (MFN) prices for selected drugs, anchored to the lowest prices paid by peer countries.
The White House projects substantial savings for Medicaid—cited publicly in the tens of billions over time—through manufacturer rebates that align state net prices with MFN benchmarks.
The model overlays Medicaid’s statutory rebate program, which since 1990 has set minimum manufacturer rebate obligations and enabled state supplemental rebates.
The policy’s significance is leverage: a nationwide buyer stance plus MFN anchors can pull down net prices faster than state-by-state bargaining alone.

What the MFN Medicaid move actually does

The administration’s announcement establishes that every state Medicaid program will access MFN-tied net prices for a defined set of prescription drugs—prices pegged to the lowest paid among developed countries—via rebate commitments from participating manufacturers. In practical terms, state Medicaid agencies continue to reimburse pharmacies as usual, then receive larger post-transaction rebates so that the program’s net price does not exceed the MFN benchmark for covered products. The White House frames this as universal state buy-in to a single discount architecture; broad participation is the catalyst for scale and negotiation credibility.

This is not an abandonment of Medicaid’s existing drug payment infrastructure. It is an overlay that resets the target for “net of rebates” spending on selected drugs. Because Medicaid’s purchasing power has long hinged on rebates rather than point-of-sale cuts, the mechanism taps familiar plumbing—rebate invoicing, settlement cycles, utilization tracking—while changing the endpoint of the calculation. That endpoint, the MFN price, becomes the de facto ceiling for what states ultimately pay, altering the negotiation baseline with manufacturers and the expectations of managed care plans that administer benefits in many states.

How this fits the long arc of Medicaid drug pricing

To see why this matters, recall how Medicaid has worked for decades. Since the Omnibus Budget Reconciliation Act of 1990, manufacturers that want their outpatient drugs covered by Medicaid must sign rebate agreements, paying a statutory rebate on each unit dispensed; states often add “supplemental” rebates on top. This framework guarantees that Medicaid captures a best-price style discount floor across brand and generic products, with federal-state cost sharing layered on the back end.

That structure has delivered real savings over time, but it leaves room for wide variation in net prices across drugs, therapeutic classes, and states—especially where supplemental bargaining power is uneven or market entrants reset the pricing table. The MFN approach addresses that variation by substituting a hard external reference for the patchwork of internal deals on select drugs. Where Medicaid once triangulated among list price, statutory rebate, and supplemental rebate, it now aims to land at or below the lowest external comparator price for the identified products, with manufacturers making up the difference through higher rebates.

Scope, savings, and the scale effect

The administration has presented this as a coast-to-coast alignment: all 50 states, D.C., and Puerto Rico under a unified MFN umbrella for designated drugs—an unusual level of state policy convergence in a domain where states often pursue bespoke tools like preferred drug lists, prior authorization, and supplemental rebate carve-outs. Savings claims highlighted publicly range from significant state-budget relief to multiyear aggregate reductions for Medicaid measured in the tens of billions—figures the White House and allied briefings have attributed to manufacturer agreements and Council of Economic Advisers estimates.

Mechanistically, the scale effect is straightforward: an MFN anchor plus nationwide participation raises the negotiating floor for states and lowers the ceiling for manufacturers simultaneously. Because Medicaid already processes rebates quarterly, the administrative lift focuses on calculating the MFN delta by drug and period, then ensuring settlement aligns with the new ceiling. In a program that covers roughly one in five Americans, even single-digit percentage reductions in net prices across a basket of high-spend drugs compound quickly; double-digit reductions compound faster.

What changes for states, plans, and manufacturers

For state Medicaid agencies, the most immediate change is predictability. Budget offices can forecast drug spending with an external reference point rather than a moving target of negotiated rebates. Pharmacy benefit managers (PBMs) and Medicaid managed care organizations (MCOs) will recalibrate formularies and utilization management knowing that the net-of-rebate price floor is lower; that can reduce pressure to steer patients to marginally cheaper alternatives when clinical equivalence is weak. For clinicians and beneficiaries, access can improve if states relax some utilization controls because the financial penalty for covering certain high-cost drugs diminishes when the net price is capped.

Manufacturers, for their part, must reconcile global pricing strategies with a large U.S. public payer now tethered to the lowest ex-U.S. price. Historically, Medicaid’s best-price rules already exerted pressure on discount corridors; MFN extends that tension by pointing to an external comparator, not just domestic transactions. The likely response varies by portfolio: companies with globally harmonized prices may absorb the change; others may revisit list price strategies abroad to manage future reference risks, a known dynamic in international reference pricing systems.

Relationship to the Medicaid Drug Rebate Program

The MFN model sits atop the statutory Medicaid Drug Rebate Program (MDRP), not outside it. Under MDRP, brand drugs owe a base rebate (a percentage of the average manufacturer price) plus an inflation-linked add-on when price growth exceeds CPI-U; generics face their own inflationary rebate. States may also secure supplemental rebates, often in exchange for preferred placement on formularies. All 50 states and D.C. participate; MDRP is the backbone that makes outpatient drugs broadly coverable and affordable in Medicaid.

By design, MFN-based rebates function as an additional reconciliation step so that the final net price matches, or falls below, the external reference for targeted drugs. In policy terms, it is a shift from “what did Medicaid’s formulas and deals yield?” to “what is the floor set by peer-country pricing—and how do rebates get us there?” The federal-state financing split then applies to the lower net spend like any other Medicaid claim, with savings shared according to each state’s federal medical assistance percentage (FMAP).

President Trump Extends Most Favored Nation Drug Pricing to Every Medicaid Program in America.
‘Thank you all for being here today as we take historic action to officially extend the benefits of our Most Favored Nation agreements on prescription drug prices to state Medicaid… pic.twitter.com/gkrDrn2Oiz

— Inspector Clueso (@IClueso) September 19, 2026

Why the claims of bipartisan uptake ring true in Medicaid’s ecosystem

States rarely walk away from large, federally facilitated rebates. The MDRP’s history shows that once a mechanism reliably lowers net costs, participation becomes universal. All states already operate within the rebate architecture; moving to a stronger, nationwide reference ceiling for selected drugs requires less political persuasion and more operational clarity. That is why a coast-to-coast alignment around an MFN overlay is credible: it uses existing pipes to deliver bigger savings on top of a framework states trust to settle correctly and on time.

What to watch as implementation matures

Three signals will separate rhetoric from durable impact. First, the breadth of the drug list: the more high-expenditure molecules included—oncology, autoimmune, specialty injectables—the larger the savings base. Second, the integrity of the MFN comparator: credible, timely foreign price data and clear conversion rules (currency, pack size, dosing) are essential. Third, the settlement math against MDRP: states will look for clean, auditable rebate accounting that shows how MFN top-offs interact with base and inflationary rebates to produce the promised net price. Each of these is tractable with the administrative infrastructure Medicaid already uses, which is precisely why the model is plausible at national scale.

Bottom line

Universal state participation in an MFN-tethered Medicaid drug pricing model takes a familiar tool—rebates—and loads it with a stronger reference anchor. It does not reinvent Medicaid pharmacy benefits; it tightens them. By consolidating state leverage and pointing it at the lowest credible external price, the policy aims to deliver large, budget-relevant reductions in net drug spending without destabilizing access. That is why all 50 states signed on, and why the center of gravity in Medicaid drug pricing is moving toward externally referenced ceilings rather than fragmented, state-by-state bargains.